Overview 

Fucosidosis is a rare type of lysosomal storage disease (LSD). LSDs are a group of genetic disorders characterised by defective lysosomal enzymes resulting in abnormal accumulation of substrates in various organ tissues. Fucosidosis is caused by mutations in the FUCA1 gene, leading to inadequate production of the enzyme alpha-L-fucosidase, which is in charge of the degradation of fucose-containing glycoproteins and glycolipids. The buildup of these macromolecules within tissues poses a significant threat to cellular processes, leading to a disruption in cellular homeostasis. 

The disease is associated with a broad spectrum of symptoms, impacting multiple systems, including the brain, skeletal and heart. Cardiovascular complications are commonly seen in other LSDs but are deemed a rare feature among severe fucosidosis patients. In this article, we will explore the cardiovascular implications of fucosidosis.

Understanding fucosidosis 

Fucosidosis is a rare lysosomal storage disease (LSD) caused by a mutation in the FUCA1 gene. It follows an autosomal recessive pattern, meaning a person will only be affected by fucosidosis when they carry two copies of the mutated pathogenic FUCA1 gene. The FUCA1 gene is responsible for the production of an enzyme known as alpha-L-fucosidase. Hence, mutation in this gene results in deficient production of alpha-L-fucosidase, which is responsible for the breakdown of complex sugars, specifically fucose-containing glycoproteins and fucose-containing glycolipids.¹ 

As a result, these complex sugar compounds will then accumulate in cells and tissues across the body, thus leading to various disruptions to normal cell functions. 

Fucosidosis is a progressive neurological disorder leading to several complications affecting multiple body systems. Some of the symptoms presented are similar to those of other LSDs.¹ 

The various symptoms exhibited are: ² 

• Coarse facial features
• Mental dysfunctions
• Intellectual disability
• Hypotonia (loss of muscle tone) 
• Growth retardation
• Movement disorders 
• Dysostosis multiplex
• Recurrent respiratory infections
• Gradual weight and muscle loss
• Abnormally enlarged organs (eg. liver, spleen, heart) 
• Rigid joints 
• Spasticity

Early studies suggested that fucosidosis can be classified into two subtypes, with type 1 being the more severe form and type 2 being the milder form. Type 1 is described as having an early onset (~ 6 months of age) and is characterised by rapid neurological deterioration, leading up to death by the age of 10. Type 2, on the other hand, typically has a later onset (~18 months to 2 years), milder and progresses slower. However, this statement is then refuted as researchers now believe that the subtypes represent a single disorder with a range of different severity and symptoms.³ 

The occurrence of the disorder is extremely low, with an estimate of <1 incidence in 200,000 live births.³ The actual incidence rate in the general population is yet to be determined, largely due to the large number of underdiagnosed cases. 

Radiologic methods and genetic testing are often required for the diagnosis of the disease.³

Cardiovascular system involvement in fucosidosis 

Cardiovascular complications are one of the many common manifestations of fucosidosis, mainly due to the impaired cellular processes caused by lysosomal dysfunctions.⁵ 

One common cardiac complication is mild mitral regurgitation, which is reported in approximately half of the fucosidosis patients studied, demonstrating the cardiovascular system's involvement in fucosidosis.⁴ 

Cardiomyopathy and cardiomegaly are presented with severe forms of fucosidosis but are rarely seen in most cases. Complex cardiac problems such as left ventricular hypertrophy, right cavity dilatation, incomplete Right Bundle Branch Block and coronary artery diseases were also observed in fucosidosis patients.¹ 

Fucosidosis is a type of LSD in which lysosomal enzymes become defective due to a genetic mutation. Lysosomes are known as the centre of degradation for organelles and macromolecules, so the breakdown product can either be stored or recycled. Hence, lysosomes play a significant role in regulating cellular processes and maintaining cellular homeostasis.⁶ 

Therefore, regular cellular processes are blundered in LSD patients as the lysosomes cannot function properly. As the macromolecules accumulate in various tissues, including the heart, the regular cellular metabolism will be largely impacted, thus resulting in cardiac complications such as coronary artery disorders, cardiomyopathy, etc.⁵ 

Nevertheless, there is a limited source of papers reporting cardiac complications observed in fucosidosis patients. This could reflect that cardiac complications are relatively uncommon in people with fucosidosis than in other LSDs.

Cardiovascular risks and prognosis in fucosidosis 

The occurrence of cardiac complications is low among fucosidosis patients, but not zero. Despite it being less common, people affected with the severe form of fucosidosis stand a higher chance of having cardiovascular complications. The severity of the disease is highly variable from one individual to the other, and this could be attributed to a number of factors. 

Genetic mutations

The severity and variability of each individual's symptoms may depend on the mutation present in the FUCA1 gene. It is believed that the different clinical manifestations and severity observed in patients are a result of the presence of several different mutations in the same gene, in addition to other environmental and genetic factors. However, more research is needed to justify this hypothesis further.¹ 

Age 

The age of onset will also contribute to the severity of the disease. Fucosidosis can develop at any age. However, the younger the age of onset, the faster the disease progresses, resulting in lethal complications, including cardiovascular diseases such as cardiomegaly, ultimately leading to early mortality. People who develop fucosidosis at an older age typically experience slower disease progression and can generally live longer lives.² 

Diagnostic and monitoring approaches 

Early detection of fucosidosis is essential for the proper management of the disease so that appropriate treatment and supportive care can be given to control its progression. Screenings and imaging procedures that are often performed to confirm the diagnosis of fucosidosis include magnetic resonance imaging (MRI), enzyme activity analysis, and molecular genetic tests.³ These tests are helpful in providing an accurate diagnosis as the symptoms presented by the disease can be similar to those of other LSDs. 

Regular screenings for cardiac complications, such as echocardiogram, electrocardiogram (ECG) and X-rays, are also conducted when an individual is suspected of fucosidosis.¹ These screenings and testing will provide your GP with adequate information about your cardiovascular system’s condition and for the detection of hypertension or any cardiovascular complications. 

When a diagnosis has been made, healthcare professionals can come up with a more comprehensive healthcare regimen for effective management of symptoms, thus halting the progression of severe complications.  

Treatment and management of cardiac complications 

Cardiovascular disorders are generally incurable. Treatments offered are targeted towards effective management and control of the complication, thereby preventing the condition from worsening. Suitable medications will be prescribed, depending on the type of disorder. 

Sometimes, heart surgery or procedures might be needed. For instance, medications for cardiomyopathy are aimed at regulating blood pressure, preventing blood clots and redressing aberrant heart rhythms. For more severe or life-threatening cases, surgical procedures or pacemaker implantations will be performed to correct abnormal heart rhythms. 

Meanwhile, treatments for fucosidosis generally focus on the management of symptoms and supportive care. Since the disease is characterised by multisystemic symptoms affecting multiple organs, a multidisciplinary approach involving a team of specialists, which includes paediatric, cardiologist, orthopaedic, neurologist, and metabolic physicians, will be necessary to design an extensive treatment plan and conduct regular screenings and assessments to monitor the progression of the disease.¹ 

To date, there is no cure for fucosidosis. However, some emerging therapies have demonstrated positive outcomes in clinical trials and preclinical studies. Haematopoietic stem cell transplantation (HSCT) was given to a small number of fucosidosis patients, and notable improvements were observed, though further research and more trials are required to assess its long-term effect and survival rate.³  

Enzyme replacement therapies for fucosidosis are currently undergoing preclinical studies, showing promising potential to advance the treatment of the disease.¹

Summary 

Cardiac complications are greatly associated with lysosomal storage diseases (LSD), but cardiac complications in fucosidosis patients are relatively rare. There is a scarce amount of literature revolving around fucosidosis and its associated cardiac complications, which may be attributed to the rarity of the disease. Many cases of fucosidosis might also be misdiagnosed because it presents with a broad range of non-specific symptoms that could be falsely interpreted as another disease. The high mortality rate among early-onset patients highlights the need for further research into fucosidosis and its connection to cardiovascular disorders. Early screenings and proactive management of fucosidosis complications are essential to slow the disease progression and enhance patients' overall quality of life.